Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1678 1758
This examiner grants 38% of resolved cases
Michael Cameron Sveiven serves in Tech Center 1700 and Art Unit 1678. With 24 resolved cases, the examiner has an allowance rate of 37.5 percent. This 37.5 percent rate indicates that prosecution here is more difficult than average, with a portion of the cases resulting in a grant. The 24 resolved cases provide an indication of the examiner's approach in this art unit.
However, the interview lift is 47.9 percent. This 47.9 percent lift suggests that while the base allowance rate is 37.5 percent, conducting an interview may significantly increase the chances of success. The median days to allowance is 1396. Practitioners should prioritize interviews as a strategy to overcome the challenges reflected in the base rate. Given the 1396-day timeline, the 47.9 percent lift is a crucial metric for applicants seeking to improve their odds of a positive outcome. This strategy is supported by the significant difference between the lift and the base allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17777011 | SILICA SHELL ENCAPSULATED POLYAROMATIC-CORE MICROPARTICLES | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18045037 | LARGE MOLECULE UNSPECIFIC CLEARANCE ASSAY | Non-Final OA | Hoffmann-La Roche Inc. |
| 17627260 | DEVICES AND METHODS FOR RAPID SCREENING OF DRUGS OF ABUSE AND OTHER ANALYTES | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18699807 | NOVEL TWO ELECTRODE-BASED CORRECTION APPROACH FOR ELIMINATION OF BIOFOULING FROM LABEL-FREE AFFINITY BIOSENSORS FOR DETECTION | Non-Final OA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18522466 | ANTI-MICROBIAL PEPTIDE (AMP) SIGNATURES FOR DIAGNOSTICS, STRATIFICATION, AND TREATMENT OF MICROBIOME-ASSOCIATED DISEASE | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18682330 | ASSAY METHODS FOR SCREENING INHIBITORS OF SICKLE CELL DISEASE, ß-THALASSEMIA, OR SICKLE CELL ß-THALASSEMIA, OR A PHENOTYPE THEREOF | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 18705460 | HOMOGENEOUS IMMUNOASSAY METHOD | Non-Final OA | Belgian Volition SRL |
| 17917479 | ENRICHMENT OF ANTIGEN-SPECIFIC ANTIBODIES FOR ANALYTIC AND THERAPEUTIC USE | Non-Final OA | Veravas, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy